 | • レポートコード：QFJ1-5852 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、118ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、代謝性疾患治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（リソソーム蓄積症、糖尿病、肥満、先天性代謝異常症、高コレステロール血症）、用途別市場規模（経口、非経口、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・代謝性疾患治療薬の市場動向 ・企業の競争状況、市場シェア ・代謝性疾患治療薬の種類別市場規模と予測2016-2027（リソソーム蓄積症、糖尿病、肥満、先天性代謝異常症、高コレステロール血症） ・代謝性疾患治療薬の用途別市場規模と予測2016-2027（経口、非経口、その他） ・代謝性疾患治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・代謝性疾患治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・代謝性疾患治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・代謝性疾患治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・代謝性疾患治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Novo Nordisk A/S、Sanofi S.A.、Boehringer Ingelheim GmbH、Eli Lilly and Company、Merck KgaA、Amgen, Inc.、AstraZeneca PLC、Actelion Pharmaceuticals Ltd.、Shire PLC、AbbVie, Inc.、Biocon Ltd.、BioMarin Pharmaceutical, Inc.、Bristol-Myers Squibb Company、Cipla, Inc.、CymaBay Therapeutics, Inc.） ・結論 |
Increasing demand for one-time therapies for metabolic disorders and rising prevalence of lifestyle diseases are the key factors that are expected to boost the growth of this market.
Market Analysis and Insights: Global Metabolic Disorder Therapeutics Market
The global Metabolic Disorder Therapeutics market size is projected to reach US$ 64560 million by 2027, from US$ 46680 million in 2020, at a CAGR of 4.3% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Metabolic Disorder Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Metabolic Disorder Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Metabolic Disorder Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Metabolic Disorder Therapeutics market.
Global Metabolic Disorder Therapeutics Scope and Market Size
Metabolic Disorder Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Metabolic Disorder Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Lysosomal Storage Diseases
Diabetes
Obesity
Inherited Metabolic Disorders
Hypercholesterolemia
Segment by Application
Oral
Parenteral
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Novo Nordisk A/S
Sanofi S.A.
Boehringer Ingelheim GmbH
Eli Lilly and Company
Merck KgaA
Amgen, Inc.
AstraZeneca PLC
Actelion Pharmaceuticals Ltd.
Shire PLC
AbbVie, Inc.
Biocon Ltd.
BioMarin Pharmaceutical, Inc.
Bristol-Myers Squibb Company
Cipla, Inc.
CymaBay Therapeutics, Inc.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Lysosomal Storage Diseases
1.2.3 Diabetes
1.2.4 Obesity
1.2.5 Inherited Metabolic Disorders
1.2.6 Hypercholesterolemia
1.3 Market by Application
1.3.1 Global Metabolic Disorder Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Oral
1.3.3 Parenteral
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Metabolic Disorder Therapeutics Market Perspective (2016-2027)
2.2 Metabolic Disorder Therapeutics Growth Trends by Regions
2.2.1 Metabolic Disorder Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Metabolic Disorder Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Metabolic Disorder Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Metabolic Disorder Therapeutics Industry Dynamic
2.3.1 Metabolic Disorder Therapeutics Market Trends
2.3.2 Metabolic Disorder Therapeutics Market Drivers
2.3.3 Metabolic Disorder Therapeutics Market Challenges
2.3.4 Metabolic Disorder Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Metabolic Disorder Therapeutics Players by Revenue
3.1.1 Global Top Metabolic Disorder Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Metabolic Disorder Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Metabolic Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Metabolic Disorder Therapeutics Revenue
3.4 Global Metabolic Disorder Therapeutics Market Concentration Ratio
3.4.1 Global Metabolic Disorder Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Metabolic Disorder Therapeutics Revenue in 2020
3.5 Metabolic Disorder Therapeutics Key Players Head office and Area Served
3.6 Key Players Metabolic Disorder Therapeutics Product Solution and Service
3.7 Date of Enter into Metabolic Disorder Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Metabolic Disorder Therapeutics Breakdown Data by Type
4.1 Global Metabolic Disorder Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Type (2022-2027)
5 Metabolic Disorder Therapeutics Breakdown Data by Application
5.1 Global Metabolic Disorder Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Metabolic Disorder Therapeutics Market Size (2016-2027)
6.2 North America Metabolic Disorder Therapeutics Market Size by Type
6.2.1 North America Metabolic Disorder Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Metabolic Disorder Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Metabolic Disorder Therapeutics Market Size by Type (2016-2027)
6.3 North America Metabolic Disorder Therapeutics Market Size by Application
6.3.1 North America Metabolic Disorder Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Metabolic Disorder Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Metabolic Disorder Therapeutics Market Size by Application (2016-2027)
6.4 North America Metabolic Disorder Therapeutics Market Size by Country
6.4.1 North America Metabolic Disorder Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Metabolic Disorder Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Metabolic Disorder Therapeutics Market Size (2016-2027)
7.2 Europe Metabolic Disorder Therapeutics Market Size by Type
7.2.1 Europe Metabolic Disorder Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Metabolic Disorder Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Metabolic Disorder Therapeutics Market Size by Type (2016-2027)
7.3 Europe Metabolic Disorder Therapeutics Market Size by Application
7.3.1 Europe Metabolic Disorder Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Metabolic Disorder Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Metabolic Disorder Therapeutics Market Size by Application (2016-2027)
7.4 Europe Metabolic Disorder Therapeutics Market Size by Country
7.4.1 Europe Metabolic Disorder Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Metabolic Disorder Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Metabolic Disorder Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Type
8.2.1 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Application
8.3.1 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region
8.4.1 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Metabolic Disorder Therapeutics Market Size (2016-2027)
9.2 Latin America Metabolic Disorder Therapeutics Market Size by Type
9.2.1 Latin America Metabolic Disorder Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Metabolic Disorder Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Metabolic Disorder Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Metabolic Disorder Therapeutics Market Size by Application
9.3.1 Latin America Metabolic Disorder Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Metabolic Disorder Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Metabolic Disorder Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Metabolic Disorder Therapeutics Market Size by Country
9.4.1 Latin America Metabolic Disorder Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Metabolic Disorder Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Metabolic Disorder Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Type
10.2.1 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Application
10.3.1 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country
10.4.1 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Novo Nordisk A/S
11.1.1 Novo Nordisk A/S Company Details
11.1.2 Novo Nordisk A/S Business Overview
11.1.3 Novo Nordisk A/S Metabolic Disorder Therapeutics Introduction
11.1.4 Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2016-2021)
11.1.5 Novo Nordisk A/S Recent Development
11.2 Sanofi S.A.
11.2.1 Sanofi S.A. Company Details
11.2.2 Sanofi S.A. Business Overview
11.2.3 Sanofi S.A. Metabolic Disorder Therapeutics Introduction
11.2.4 Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2016-2021)
11.2.5 Sanofi S.A. Recent Development
11.3 Boehringer Ingelheim GmbH
11.3.1 Boehringer Ingelheim GmbH Company Details
11.3.2 Boehringer Ingelheim GmbH Business Overview
11.3.3 Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Introduction
11.3.4 Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2016-2021)
11.3.5 Boehringer Ingelheim GmbH Recent Development
11.4 Eli Lilly and Company
11.4.1 Eli Lilly and Company Company Details
11.4.2 Eli Lilly and Company Business Overview
11.4.3 Eli Lilly and Company Metabolic Disorder Therapeutics Introduction
11.4.4 Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2016-2021)
11.4.5 Eli Lilly and Company Recent Development
11.5 Merck KgaA
11.5.1 Merck KgaA Company Details
11.5.2 Merck KgaA Business Overview
11.5.3 Merck KgaA Metabolic Disorder Therapeutics Introduction
11.5.4 Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2016-2021)
11.5.5 Merck KgaA Recent Development
11.6 Amgen, Inc.
11.6.1 Amgen, Inc. Company Details
11.6.2 Amgen, Inc. Business Overview
11.6.3 Amgen, Inc. Metabolic Disorder Therapeutics Introduction
11.6.4 Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2016-2021)
11.6.5 Amgen, Inc. Recent Development
11.7 AstraZeneca PLC
11.7.1 AstraZeneca PLC Company Details
11.7.2 AstraZeneca PLC Business Overview
11.7.3 AstraZeneca PLC Metabolic Disorder Therapeutics Introduction
11.7.4 AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2016-2021)
11.7.5 AstraZeneca PLC Recent Development
11.8 Actelion Pharmaceuticals Ltd.
11.8.1 Actelion Pharmaceuticals Ltd. Company Details
11.8.2 Actelion Pharmaceuticals Ltd. Business Overview
11.8.3 Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Introduction
11.8.4 Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2016-2021)
11.8.5 Actelion Pharmaceuticals Ltd. Recent Development
11.9 Shire PLC
11.9.1 Shire PLC Company Details
11.9.2 Shire PLC Business Overview
11.9.3 Shire PLC Metabolic Disorder Therapeutics Introduction
11.9.4 Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2016-2021)
11.9.5 Shire PLC Recent Development
11.10 AbbVie, Inc.
11.10.1 AbbVie, Inc. Company Details
11.10.2 AbbVie, Inc. Business Overview
11.10.3 AbbVie, Inc. Metabolic Disorder Therapeutics Introduction
11.10.4 AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business (2016-2021)
11.10.5 AbbVie, Inc. Recent Development
11.11 Biocon Ltd.
11.11.1 Biocon Ltd. Company Details
11.11.2 Biocon Ltd. Business Overview
11.11.3 Biocon Ltd. Metabolic Disorder Therapeutics Introduction
11.11.4 Biocon Ltd. Revenue in Metabolic Disorder Therapeutics Business (2016-2021)
11.11.5 Biocon Ltd. Recent Development
11.12 BioMarin Pharmaceutical, Inc.
11.12.1 BioMarin Pharmaceutical, Inc. Company Details
11.12.2 BioMarin Pharmaceutical, Inc. Business Overview
11.12.3 BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Introduction
11.12.4 BioMarin Pharmaceutical, Inc. Revenue in Metabolic Disorder Therapeutics Business (2016-2021)
11.12.5 BioMarin Pharmaceutical, Inc. Recent Development
11.13 Bristol-Myers Squibb Company
11.13.1 Bristol-Myers Squibb Company Company Details
11.13.2 Bristol-Myers Squibb Company Business Overview
11.13.3 Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Introduction
11.13.4 Bristol-Myers Squibb Company Revenue in Metabolic Disorder Therapeutics Business (2016-2021)
11.13.5 Bristol-Myers Squibb Company Recent Development
11.14 Cipla, Inc.
11.14.1 Cipla, Inc. Company Details
11.14.2 Cipla, Inc. Business Overview
11.14.3 Cipla, Inc. Metabolic Disorder Therapeutics Introduction
11.14.4 Cipla, Inc. Revenue in Metabolic Disorder Therapeutics Business (2016-2021)
11.14.5 Cipla, Inc. Recent Development
11.15 CymaBay Therapeutics, Inc.
11.15.1 CymaBay Therapeutics, Inc. Company Details
11.15.2 CymaBay Therapeutics, Inc. Business Overview
11.15.3 CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Introduction
11.15.4 CymaBay Therapeutics, Inc. Revenue in Metabolic Disorder Therapeutics Business (2016-2021)
11.15.5 CymaBay Therapeutics, Inc. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Lysosomal Storage Diseases
Table 3. Key Players of Diabetes
Table 4. Key Players of Obesity
Table 5. Key Players of Inherited Metabolic Disorders
Table 6. Key Players of Hypercholesterolemia
Table 7. Global Metabolic Disorder Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Metabolic Disorder Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Metabolic Disorder Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Metabolic Disorder Therapeutics Market Share by Regions (2016-2021)
Table 11. Global Metabolic Disorder Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Metabolic Disorder Therapeutics Market Share by Regions (2022-2027)
Table 13. Metabolic Disorder Therapeutics Market Trends
Table 14. Metabolic Disorder Therapeutics Market Drivers
Table 15. Metabolic Disorder Therapeutics Market Challenges
Table 16. Metabolic Disorder Therapeutics Market Restraints
Table 17. Global Metabolic Disorder Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Metabolic Disorder Therapeutics Market Share by Players (2016-2021)
Table 19. Global Top Metabolic Disorder Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Metabolic Disorder Therapeutics as of 2020)
Table 20. Ranking of Global Top Metabolic Disorder Therapeutics Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Metabolic Disorder Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Metabolic Disorder Therapeutics Product Solution and Service
Table 24. Date of Enter into Metabolic Disorder Therapeutics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Metabolic Disorder Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Metabolic Disorder Therapeutics Revenue Market Share by Type (2016-2021)
Table 28. Global Metabolic Disorder Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Metabolic Disorder Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Metabolic Disorder Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Metabolic Disorder Therapeutics Revenue Market Share by Application (2016-2021)
Table 32. Global Metabolic Disorder Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Metabolic Disorder Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Metabolic Disorder Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Metabolic Disorder Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Metabolic Disorder Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Metabolic Disorder Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Metabolic Disorder Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Metabolic Disorder Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Metabolic Disorder Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Metabolic Disorder Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Metabolic Disorder Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Metabolic Disorder Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Metabolic Disorder Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Metabolic Disorder Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Metabolic Disorder Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Metabolic Disorder Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Metabolic Disorder Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Metabolic Disorder Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Metabolic Disorder Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Metabolic Disorder Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Metabolic Disorder Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Metabolic Disorder Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Metabolic Disorder Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Metabolic Disorder Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Metabolic Disorder Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Metabolic Disorder Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Metabolic Disorder Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Metabolic Disorder Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 64. Novo Nordisk A/S Company Details
Table 65. Novo Nordisk A/S Business Overview
Table 66. Novo Nordisk A/S Metabolic Disorder Therapeutics Product
Table 67. Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 68. Novo Nordisk A/S Recent Development
Table 69. Sanofi S.A. Company Details
Table 70. Sanofi S.A. Business Overview
Table 71. Sanofi S.A. Metabolic Disorder Therapeutics Product
Table 72. Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 73. Sanofi S.A. Recent Development
Table 74. Boehringer Ingelheim GmbH Company Details
Table 75. Boehringer Ingelheim GmbH Business Overview
Table 76. Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Product
Table 77. Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 78. Boehringer Ingelheim GmbH Recent Development
Table 79. Eli Lilly and Company Company Details
Table 80. Eli Lilly and Company Business Overview
Table 81. Eli Lilly and Company Metabolic Disorder Therapeutics Product
Table 82. Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 83. Eli Lilly and Company Recent Development
Table 84. Merck KgaA Company Details
Table 85. Merck KgaA Business Overview
Table 86. Merck KgaA Metabolic Disorder Therapeutics Product
Table 87. Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 88. Merck KgaA Recent Development
Table 89. Amgen, Inc. Company Details
Table 90. Amgen, Inc. Business Overview
Table 91. Amgen, Inc. Metabolic Disorder Therapeutics Product
Table 92. Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 93. Amgen, Inc. Recent Development
Table 94. AstraZeneca PLC Company Details
Table 95. AstraZeneca PLC Business Overview
Table 96. AstraZeneca PLC Metabolic Disorder Therapeutics Product
Table 97. AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 98. AstraZeneca PLC Recent Development
Table 99. Actelion Pharmaceuticals Ltd. Company Details
Table 100. Actelion Pharmaceuticals Ltd. Business Overview
Table 101. Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 102. Actelion Pharmaceuticals Ltd. Recent Development
Table 103. Shire PLC Company Details
Table 104. Shire PLC Business Overview
Table 105. Shire PLC Metabolic Disorder Therapeutics Product
Table 106. Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 107. Shire PLC Recent Development
Table 108. AbbVie, Inc. Company Details
Table 109. AbbVie, Inc. Business Overview
Table 110. AbbVie, Inc. Metabolic Disorder Therapeutics Product
Table 111. AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 112. AbbVie, Inc. Recent Development
Table 113. Biocon Ltd. Company Details
Table 114. Biocon Ltd. Business Overview
Table 115. Biocon Ltd. Metabolic Disorder Therapeutics Product
Table 116. Biocon Ltd. Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 117. Biocon Ltd. Recent Development
Table 118. BioMarin Pharmaceutical, Inc. Company Details
Table 119. BioMarin Pharmaceutical, Inc. Business Overview
Table 120. BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Product
Table 121. BioMarin Pharmaceutical, Inc. Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 122. BioMarin Pharmaceutical, Inc. Recent Development
Table 123. Bristol-Myers Squibb Company Company Details
Table 124. Bristol-Myers Squibb Company Business Overview
Table 125. Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Product
Table 126. Bristol-Myers Squibb Company Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 127. Bristol-Myers Squibb Company Recent Development
Table 128. Cipla, Inc. Company Details
Table 129. Cipla, Inc. Business Overview
Table 130. Cipla, Inc. Metabolic Disorder Therapeutics Product
Table 131. Cipla, Inc. Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 132. Cipla, Inc. Recent Development
Table 133. CymaBay Therapeutics, Inc. Company Details
Table 134. CymaBay Therapeutics, Inc. Business Overview
Table 135. CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Product
Table 136. CymaBay Therapeutics, Inc. Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 137. CymaBay Therapeutics, Inc. Recent Development
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Metabolic Disorder Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Lysosomal Storage Diseases Features
Figure 3. Diabetes Features
Figure 4. Obesity Features
Figure 5. Inherited Metabolic Disorders Features
Figure 6. Hypercholesterolemia Features
Figure 7. Global Metabolic Disorder Therapeutics Market Share by Application: 2020 VS 2027
Figure 8. Oral Case Studies
Figure 9. Parenteral Case Studies
Figure 10. Others Case Studies
Figure 11. Metabolic Disorder Therapeutics Report Years Considered
Figure 12. Global Metabolic Disorder Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Metabolic Disorder Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Metabolic Disorder Therapeutics Market Share by Regions: 2020 VS 2027
Figure 15. Global Metabolic Disorder Therapeutics Market Share by Regions (2022-2027)
Figure 16. Global Metabolic Disorder Therapeutics Market Share by Players in 2020
Figure 17. Global Top Metabolic Disorder Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Metabolic Disorder Therapeutics as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Metabolic Disorder Therapeutics Revenue in 2020
Figure 19. Global Metabolic Disorder Therapeutics Revenue Market Share by Type (2016-2021)
Figure 20. Global Metabolic Disorder Therapeutics Revenue Market Share by Type (2022-2027)
Figure 21. North America Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Metabolic Disorder Therapeutics Market Share by Type (2016-2027)
Figure 23. North America Metabolic Disorder Therapeutics Market Share by Application (2016-2027)
Figure 24. North America Metabolic Disorder Therapeutics Market Share by Country (2016-2027)
Figure 25. United States Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Metabolic Disorder Therapeutics Market Share by Type (2016-2027)
Figure 29. Europe Metabolic Disorder Therapeutics Market Share by Application (2016-2027)
Figure 30. Europe Metabolic Disorder Therapeutics Market Share by Country (2016-2027)
Figure 31. Germany Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Metabolic Disorder Therapeutics Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Metabolic Disorder Therapeutics Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Metabolic Disorder Therapeutics Market Share by Region (2016-2027)
Figure 41. China Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Metabolic Disorder Therapeutics Market Share by Type (2016-2027)
Figure 49. Latin America Metabolic Disorder Therapeutics Market Share by Application (2016-2027)
Figure 50. Latin America Metabolic Disorder Therapeutics Market Share by Country (2016-2027)
Figure 51. Mexico Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Metabolic Disorder Therapeutics Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Metabolic Disorder Therapeutics Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Metabolic Disorder Therapeutics Market Share by Country (2016-2027)
Figure 57. Turkey Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Novo Nordisk A/S Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021)
Figure 61. Sanofi S.A. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021)
Figure 62. Boehringer Ingelheim GmbH Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021)
Figure 63. Eli Lilly and Company Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021)
Figure 64. Merck KgaA Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021)
Figure 65. Amgen, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021)
Figure 66. AstraZeneca PLC Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021)
Figure 67. Actelion Pharmaceuticals Ltd. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021)
Figure 68. Shire PLC Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021)
Figure 69. AbbVie, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021)
Figure 70. Biocon Ltd. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021)
Figure 71. BioMarin Pharmaceutical, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021)
Figure 72. Bristol-Myers Squibb Company Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021)
Figure 73. Cipla, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021)
Figure 74. CymaBay Therapeutics, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed
世界のメタボリックシンドローム市場規模・現状・予測（2021年-2027年） Metabolic syndrome is a cluster of conditions — increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels — that occur together, increasing your risk of heart disease, stroke and diabetes. One of the upcoming trends gaining traction…- 世界の遺伝性遺伝性疾患用遺伝子治療市場規模・現状・予測（2021年-2027年） In the medicine field gene therapy (also called human gene transfer) is the therapeutic delivery of nucleic acid into a patient's cells as a drug to treat disease.A genetic disorder is a genetic problem caused by one or more abnormalities formed in the genome. Gene therapy has the potential to cure …
- 世界の心的外傷後ストレス障害治療薬市場規模・現状・予測（2021年-2027年） The main treatments for post-traumatic stress disorder (PTSD) are psychological therapies and medication. Market Analysis and Insights: Global Post-Traumatic Stress Disorder Therapeutics Market The global Post-Traumatic Stress Disorder Therapeutics market size is projected to reach US$ XX million by…
- 世界の神経変性疾患治療薬市場規模・現状・予測（2021年-2027年） The goal of therapeutic development for neurodegenerative disorders is to develop drugs that slow down or stop the neurodegenerative process. So-called neuroprotective, or disease-modifying, therapies would not only treat the symptoms but slow the continued loss of neurons in disease. Market Analysi…
- 世界のCDKL5欠乏症（CDD）市場規模・現状・予測（2021年-2027年） CDKL5 deficiency disorder (CDD) is a rare developmental epileptic encephalopathy (DEE), X-linked genetic condition which results in early-onset, difficult to control seizures and severe neuro-developmental impairment. CDKL5 stands for cyclin-dependent kinase-like 5 and mutations in this gene were fi…